Qynapse

The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust.

Headquartered in France, in the United States and in Canada, the Qynapse team, with our world-renowned team of scientific and clinical partners, is wholly dedicated to aspiring to bring the entire neuroscience community and their patients the clearest, most accurate and reliable predictors and objective measures of devastating CNS disorders such as Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.

We are constantly evolving, refining and testing our FDA-cleared and CE-marked neuroimaging software platform, QyScore®, which is powered by proprietary Artificial Intelligence, to provide physicians, pharma researchers and payers a reliable layer of precision when reading an MRI scan. QyPredict®, our predictive research-use-only platform powered by machine learning algorithms, is being designed to transform what we know about CNS disease trajectory, with the potential to dramatically increase the likelihood of a successful clinical trial.

Together, we are moving forward to a brighter and more accurate future of diagnosis and treatment for central nervous system diseases.

Company’s Keywords:

medical device, neurology, neuroimaging, artificial intelligence, diagnosis, prediction, disease trajectory, monitoring, drug efficacy, drug safety, personalized medicine, clinical trials, clinical research, central nervous system, azheimers, parkinsons, dementia, multiple sclerosis, stroke, psychiatry